Zhejiang Cuize Biopharmaceutical

Zhejiang Cuize Biopharmaceutical is a clinical-stage biopharmaceutical company based in Hangzhou, China, dedicated to the development of innovative small molecule drugs for autoimmune diseases and oncology. The company's research focuses on highly selective kinase inhibitors, with a lead program, CZ-001, targeting Janus kinase 1 (JAK1). CZ-001 is currently in Phase 2 clinical trials for atopic dermatitis and is being explored for other inflammatory conditions. Cuize Biopharmaceutical leverages its internal medicinal chemistry expertise to create a pipeline of differentiated therapies aimed at addressing significant unmet medical needs in the global market.